SYSTEMATIC REVIEW article
Front. Pharmacol.
Sec. Gastrointestinal and Hepatic Pharmacology
From Mechanisms to Anti‑fibrotic Drugs in Hepatic Stellate Cell Research: A Global Bibliometric Analysis with Patent and Clinical Perspectives (2000–2025)
Provisionally accepted
- 1Urumqi Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Xinjiang, China
- 2Xi'an Medical University, Xi'an, China
- 3Baoji Hospital Affiliated to Xi'an Medical University, Baoji, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Liver fibrosis (LF) is a progressive condition that can advance to cirrhosis and liver failure, posing a major global health burden. Hepatic stellate cells (HSCs) are central to LF pathogenesis via extracellular matrix (ECM) production and inflammatory regulation, and have been widely explored as therapeutic targets. Methods: We searched the Web of Science Core Collection (WoSCC), Scopus, and PubMed for English-language publications using the keywords "liver fibrosis" and "stellate cells." Additionally, ClinicalTrials.gov was queried for clinical trials, and the Innojoy search engine was used for patents. Analyses were performed using CiteSpace (version 6.2.R4), VOSviewer, R, and Microsoft Excel to examine publication trends, collaboration and citation structures, keyword co-occurrence, clustering, citation bursts, and International Patent Classification (IPC) profiles. Results: From 2000 to 2025, annual publications increased from 3 to 50 (≈16.7‑ fold), totaling 1,042 papers; China led output (n=672), followed by the USA (n=162), spanning hepatology and pharmacology. Thirteen thematic clusters were identified across etiology, molecular mechanisms, and therapeutics/delivery, with targeted delivery and intervention emerging as the leading frontier. Burst terms highlighted sustained reliance on rodent in vivo models (rats/mice; carbon tetrachloride injury) alongside hepatocellular carcinoma‑ related signals. The patent landscape was dominated by therapeutic‑ use and small‑ molecule classes (A61P 1/16; A61K 31/), with expansion to specialized dosage forms and combination regimens (A61K 9/00; A61K 45/06) and multimodal platforms involving nucleic acids (C12N 15/113) and antibodies (C07K 16/18). Clinical trials shifted from early small molecule monotherapies to more diversified, combinable regimens. Conclusion: Integrating bibliometrics with patent and clinical landscapes, this study delineates an evolution from mechanism discovery to precision intervention in HSC - focused LF research. Future priorities include improving target/tissue specificity and advancing multimodal, patient stratified strategies to enhance translational efficiency.
Keywords: Anti-fibrotic therapy, Bibliometrics, clinical trials, Hepatic Stellate Cells, liver fibrosis, Patents, targeted delivery
Received: 28 Oct 2025; Accepted: 26 Nov 2025.
Copyright: © 2025 Mao, Chen, Wabul, Liu, Zhao, Zhang, Guan and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Bin Li
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.